certificate of analysis is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
=== Microtemplate polymerization === The addition of a monomer precursor solution and crosslinking agent to a microtemplate, or mold-type device, can initiate polymerization and the formation of nanogels. This method can be used to create nanogels in specific shapes and load them with various small molecules. Lithographic microtemplate polymerization is a similar process that uses a photoinitiator and light to trigger the formation of nanogels. Lithographic microtemplate polymerization can produce smaller nanogels on a length scale of <200 nm, which has a higher resolution compared to microtemplate polymerization that does not require a photoinitiator.
These are usually hydroxyapatite- or tricalcium phosphate-based granules formed into a coralline or trabecular structure to mimic the structure of cancellous bone. They act solely as an osteoconductive matrix. Some manufacturers have recently begun supplying these products with soluble bone-forming factors such as bone morphogenetic protein to attempt to create a synthetic product with osteoinductive properties. Titanium alloy implants (plates and screws) can be attached to the two bones to hold them together in a position which favors bone growth. A combination of the above methods is also commonly employed to facilitate bony fusion. At the completion of surgery and healing, which takes place over a period of several weeks to over a year, the two adjoining bones are fused and no motion takes place between them. This can have the effect of strengthening the bones, as in anterior cervical fusion.
== Presentation == The most characteristic symptom of acrogeria is thin, atrophic skin with mottled pigmentation and telangiectasia, most severe in the limbs and extremities. This is accompanied by easy bruising, hyperkeratosis, and a loss of subcutaneous fat, which is replaced by connective tissue. Patients have a facies with a pinched face, hollow cheeks, prominent eyes without exophthalmos, a beak-like nose and thin lips. Though the hair and nails are normal in many cases, alopecia and nail dystrophies, such as onychogryphosis and koilonychia, have been reported. Stature is short in some patients and normal in others. The general skeletal structure is unremarkable, but acrogeria results in delayed closure of the cranial sutures, notching of the mandible, and micrognathia; and may also coincide with spina bifida, clubfoot and congenital dislocation of the hips. Sexual development, including the development of secondary sex characteristics, is normal, and so is intelligence. There is no correlation of acrogeria with metabolic, opthamological or cardiovascular disorders, and patients have a normal life expectancy. Similarities between the clinical features of acrogeria and Werner's syndrome have been observed.
Confluentic acid is an organic compound belonging to the chemical class known as depsides. It serves as a secondary metabolite in certain lichens and plays a role in distinguishing closely related species within the genus Porpidia. In 1899, Friedrich Wilhelm Zopf isolated a compound from Lecidea confluens, which he initially named confluentin and noted for its melting point of 147–148 °C. This substance demonstrated the ability to turn litmus paper red and, when interacting with alkali, decomposed into carbon dioxide and phenol-like compounds. Zopf subsequently revised the chemical formula and melting point of the compound. Siegfried Huneck renamed it confluentinic acid in 1962, characterising it as optically inactive, with distinct colour reactions and solubility properties, and determined its molecular formula as C28H36O8. Confluentic acid can be identified using thin-layer chromatography and high-performance liquid chromatography. An alternative visual detection method involves examining the lichen's thallus or apothecium (fruiting body) under a microscope on a slide treated with potassium hydroxide, which reveals oil droplets indicative of confluentic acid. Several structural analogues of confluentic acid have been isolated from a variety of lichen species.
=== Chemical descriptor based === In this approach, descriptors quantifying various electronic, geometric, or steric properties of a molecule are computed and used to develop a QSAR. This approach is different from the fragment (or group contribution) approach in that the descriptors are computed for the system as whole rather than from the properties of individual fragments. This approach is different from the 3D-QSAR approach in that the descriptors are computed from scalar quantities (e.g., energies, geometric parameters) rather than from 3D fields. An example of this approach is the QSARs developed for olefin polymerization by half sandwich compounds.
Sources: en.wikipedia.org
== Genetics == The gene encoding the enzyme is referred to as DDC is located on chromosome 7 in humans. It consists of 15 exons encoding a protein of 480 amino acids. Single nucleotide polymorphisms and other gene variations have been investigated in relation to neuropsychiatric disorders, for example, a one-base pair deletion at 601 and a four-base pair deletion at 722–725 in exon 1 in relation to bipolar disorder and autism. No direct correlation between gene variation and autism was found. More than 50 mutations of DDC have been correlated with AADC deficiency. This condition is most prevalent in Asia, presumably due to the founder effect. Alternative splicing events and promoters have been observed that lead to various forms of the AADC enzyme. Unique usage of certain promoters leads to transcription of only the first exon to produce an extra-neuronal isoform, and splicing of exon 3 leads to a product devoid of enzymatic activity. Analyses via porcine specimens have elucidated two AADC isoforms – resulting from exclusion of exon 5 and exons 5 and 6 – that lack a portion of the decarboxylating domain.
==== Point contact on a (3D) half-space ==== Analogously to the Flamant solution for the 2D half-plane, fundamental solutions are known for the linearly elastic 3D half-space as well. These were found by Boussinesq for a concentrated normal load and by Cerruti for a tangential load. See the section on this in Linear elasticity.
Albany is the home of the main campus of a two-year junior college called Linn-Benton Community College, which was established in 1966. The college offers certificates and associate degrees and has many transfer and dual enrollment programs with OSU. LBCC offers 47 areas of study and programs, serves over 18,000 full- and part-time students and is supported financially through tuition, property taxes and the State of Oregon. The Albany area has also been served since 1979 by the Greater Albany Public School District, including West Albany High School, and South Albany High School, which have a combined enrollment of approximately 2,700 students. Albany is also served by Albany Options School as an alternative to traditional school for grades 6 through 12. In total Greater Albany Public School District serves roughly 8,900 students throughout its 23 different schools. Along with the K-12 schools Albany also offers student services at the Maple Lawn Preschool.
== Types of nuclides == Although the words nuclide and isotope are often used interchangeably, being isotopes is actually only one relation between nuclides. The following table names some other relations.
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.